Fig. 1From: Ten years of treatment with ruxolitinib for myelofibrosis: a review of safetyJAK signaling in MF and ruxolitinib mechanism of action. BM bone marrow, JAK Janus kinase, MF myelofibrosis, P phosphorylation, STAT signal transducer and activator of transcriptionBack to article page